ENSC

Ensysce Biosciences, Inc. (ENSC) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended September 30, 2025. Ensysce Biosciences, Inc. is a clinical-stage biotechnology company focused on developing safer prescription drugs, specifically abuse-resistant and overdose-protected opioid therapies. The company's lead product candidate, PF614 (an extended-release TAAP prodrug of oxycodone), is in Phase 3 clinical development, while PF614-MPAR is in Phase 1b. The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Note: The company does not report traditional profit margins as it is pre-revenue from product sales. Revenue consists entirely of federal research grants.

Material Changes vs. Prior Period

• Revenue Decline: Federal grant revenue decreased by approximately $2.9 million in the three months ended September 30, 2025, compared to the same period in 2024. This is primarily due to the timing of research activities under the MPAR grant and the conclusion of the OUD grant in August 2024.
• Increased Operating Expenses: Total operating expenses rose by $1.46 million (53%) in the three months ended September 30, 2025, compared to the prior year period. Research and Development (R&D) expenses increased by $1.26 million, driven by increased clinical and pre-clinical activity for PF614 and PF614-MPAR.
• Net Loss Expansion: The company swung from a net income of $661,769 in Q3 2024 to a net loss of $3.73 million in Q3 2025. This shift is attributed to the drop in grant revenue and the significant increase in R&D spending.
• Capital Structure: The company completed a 1-for-15 reverse stock split in December 2024. As of September 30, 2025, there were 3,181,074 shares of common stock outstanding.

Guidance, Outlook, and Risks

• Liquidity and Going Concern: Management states that existing cash resources are sufficient to fund operations into the late first quarter of 2026. The filing explicitly raises "substantial doubt" about the company's ability to continue as a going concern without additional financing.
• Recent Financing: In November 2025 (subsequent to the reporting period), the company completed a convertible preferred stock offering with gross proceeds of $4 million, with potential for up to $16 million in additional funding over the next 24 months.
• Outlook: The company expects expenses to remain elevated as it advances clinical trials. Future profitability is dependent on the successful development and commercialization of product candidates, which is highly uncertain.
• Key Risks:
  • Failure to raise additional capital on acceptable terms.
  • Delisting from Nasdaq if listing standards are not maintained.
  • Clinical trial failures or inability to replicate preclinical results.
  • Reliance on third-party CROs and CMOs.
  • Regulatory approval delays or denials.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.7 million cash balance against the $7.3 million in open purchase orders and contractual commitments.
• Grant Funding: Confirm the status and remaining balance of the MPAR grant ($8.9 million remaining as of Sept 30, 2025) and the timeline for future disbursements.
• Debt Obligations: Review the terms of the $216,000 principal balance on the 2023 Notes held by a board member and the associated forbearance agreement expiring April 25, 2026.
• Subsequent Financing: Validate the terms and closing of the November 2025 convertible preferred stock offering ($4 million initial tranche).
• Warrant Inducements: Assess the dilution impact of recent warrant inducements (April 2025) and the exercise of warrants at reduced prices.